Patent application number | Description | Published |
20080279909 | Immobilized Biologically Active Entities Having A High Degree of Biological Activity Following Sterilization - The present invention relates to immobilized biologically active entities that retain significant biological activity following sterilization of the immobilized biologically active entities. | 11-13-2008 |
20080281393 | Bioabsorbable Self-Expanding Endolumenal Devices - The present invention is directed to bioabsorbable self-expanding medical devices for use inside or outside body conduits that self-expand at, or below, normal human body temperature without requisite for a polymeric thermal transition. | 11-13-2008 |
20100233266 | ARTICLES AND METHODS OF TREATING VASCULAR CONDITIONS - The present invention relates to articles and methods of treating vascular conditions with a thixotropic, turbid, bioactive agent-containing gel material capable of being essentially removed from an implantation site upon re-establishment of fluid flow at the implantation site. | 09-16-2010 |
20100272775 | IMMOBILIZED BIOLOGICALLY ACTIVE ENTITIES HAVING A HIGH DEGREE OF BIOLOGICAL ACTIVITY FOLLOWING STERILIZATION - The present invention relates to immobilized biologically active entities that retain significant biological activity following sterilization of the immobilized biologically active entities. | 10-28-2010 |
20110064781 | NOVEL HEPARIN ENTITIES AND METHODS OF USE - The present invention relates to immobilized biologically active entities that retain a significant biological activity following manipulation. The invention also comprises a medical substrate comprising a heparin entity bound onto a substrate via at least one heparin molecule, wherein said bound heparin entity is heparinase-1 sensitive. | 03-17-2011 |
20110065085 | NOVEL HEPARIN ENTITIES AND METHODS OF USE - The present invention relates to immobilized biologically active entities that retain a significant biological activity following manipulation. The invention also comprises a medical substrate comprising a heparin entity bound onto a substrate via at least one heparin molecule, wherein said bound heparin entity is heparinase-1 sensitive. | 03-17-2011 |
20110098797 | DRUG ELUTING COMPOSITE - The present invention relates to materials having therapeutic compositions releasably contained within the materials. The materials are configured to release therapeutic compositions at a desired rate. The present invention also relates to devices incorporating the materials. | 04-28-2011 |
20110112618 | DRUG ELUTING COMPOSITE - The present invention relates to materials having therapeutic compositions releasably contained within the materials. The materials are configured to release therapeutic compositions at a desired rate. The present invention also relates to devices incorporating the materials. | 05-12-2011 |
20110268781 | DRUG ELUTING COMPOSITE - The present invention relates to materials having therapeutic compositions releasably contained within the materials. The materials are configured to release therapeutic compositions at a desired rate. The present invention also relates to devices incorporating the materials. | 11-03-2011 |
20110293689 | IMMOBILIZED BIOLOGICALLY ACTIVE ENTITIES HAVING A HIGH DEGREE OF BIOLOGICAL ACTIVITY - The present invention relates to immobilized biologically active entities having heparin cofactor II binding activity. | 12-01-2011 |
20120065721 | THERMOPLASTIC FLUOROPOLYMER-COATED MEDICAL DEVICES - A medical device provided with at least a partial surface coating of a thermoplastic copolymer of tetrafluoroethylene and perfluoroalkylvinylether that is free of cross-linking monomers and curing agents. The fluoropolymer coating is preferably an amorphous thermoplastic, is highly inert and biocompatible, has elastomeric characteristics that provide desirable mechanical properties such as good flexibility and durability. These characteristics allow the coating to be considered “functionally transparent” because it withstands mechanical deformations required for the assembly, deployment, expansion, and placement of medical devices, without any adverse effect on the mechanical and biological functionality of the coated device. Further, its inertness, derived from the perfluorocarbon structure, contributes to its functionally transparent nature. The coating can be provided with various liquid or solid additives, can be loaded with large quantities of additives including a wide range of therapeutic agents, and has excellent drug elution characteristics when elutable additives are used. | 03-15-2012 |
20120207791 | IMMOBILIZED BIOLOGICALLY ACTIVE ENTITIES HAVING A HIGH DEGREE OF BIOLOGICAL ACTIVITY - The present invention relates to immobilized biologically active entities having heparin cofactor II binding activity. | 08-16-2012 |
20120310210 | ELUTING MEDICAL DEVICES - The invention is directed to eluting medical devices that enable consistent “on-demand” delivery of therapeutic agents to a vessel. The medical device of the current invention comprises an expandable member, a hydrophilic coating comprising at least one therapeutic agent about the expandable member or structural layer and an outer sheath with a variably permeable microstructure. The design and methods disclosed herein ensures that therapeutic agent delivery occurs essentially only during expansion of the expandable member, minimizing coating and/or therapeutic agent loss to the bloodstream and providing controlled delivery to the treatment site. | 12-06-2012 |
20130035665 | Polymer-Based Occlusion Devices, Systems and Methods - A method of occluding includes imbibing a porous elongate element comprised of ePTFE with a calcium-containing solution. The method also includes delivering, via a delivery catheter, the calcium-imbibed porous elongate element to a target occlusion site. The method further includes administering, after the calcium-imbibed porous elongate element has been completely delivered to the target occlusion site and resides entirely within a volume defined by the target occlusion site, an alginate-containing solution to the target occlusion site. | 02-07-2013 |
20130150284 | IMMOBILIZED BIOLOGICALLY ACTIVE ENTITIES HAVING A HIGH DEGREE OF BIOLOGICAL ACTIVITY - The present invention relates to immobilized biologically active entities having heparin cofactor II binding activity. | 06-13-2013 |
20130253426 | ELUTING MEDICAL DEVICES - The invention is directed to eluting medical devices that enable consistent “on-demand” delivery of therapeutic agents to a vessel. The medical device of the current invention comprises an expandable member, a hydrophilic coating comprising at least one therapeutic agent about the expandable member or structural layer and an outer sheath with a variably permeable microstructure. The design and methods disclosed herein ensures that therapeutic agent delivery occurs essentially only during expansion of the expandable member, minimizing coating and/or therapeutic agent loss to the bloodstream and providing controlled delivery to the treatment site. | 09-26-2013 |
20140066897 | RETRACTABLE SHEATH DEVICES, SYSTEMS, AND METHODS - The invention is directed to delivery medical devices that enable consistent “on-demand” delivery of therapeutic agents to a vessel. The medical device of the current invention comprises retractable sheath comprising neckable elements. The medical device of the current invention comprises an expandable member, a hydrophilic coating comprising at least one therapeutic agent about the expandable member or structural layer and a retractable outer sheath with a selectively permeable microstructure. The design and methods disclosed herein ensures that therapeutic agent delivery occurs essentially only during retraction of the outer sheath, minimizing coating and/or therapeutic agent loss to the bloodstream and providing controlled delivery to the treatment site. | 03-06-2014 |
20140072514 | POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS - The present disclosure is directed to a class of fluorinated copolymers, such as PTFE copolymers, that can be dissolved in low toxicity solvents, such as Class III Solvents, and that enable the creation of stable water-in-solvent emulsions comprising the fluorinated copolymers dissolved in a low toxicity solvents and a hydrophilic agent (e.g., a therapeutic agent) dissolved in an aqueous solvent, such as water or saline. | 03-13-2014 |
20140072518 | POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS - The present disclosure is directed to a class of fluorinated copolymers, such as a PTFE copolymers, that can be dissolved in low toxicity solvents, such as Class III Solvents, and that enable the creation of stable water-in-solvent emulsions comprising the fluorinated copolymers dissolved in a low toxicity solvents and a hydrophilic agent (e.g., a therapeutic agent) dissolved in an aqueous solvent, such as water or saline. | 03-13-2014 |
20140105955 | THERMOPLASTIC FLUOROPOLYMER-COATED MEDICAL DEVICES - A medical device provided with at least a partial surface coating of a thermoplastic copolymer of tetrafluoroethylene and perfluoroalkylvinylether that is free of cross-linking monomers and curing agents. The fluoropolymer coating is preferably an amorphous thermoplastic, is highly inert and biocompatible, has elastomeric characteristics that provide desirable mechanical properties such as good flexibility and durability. These characteristics allow the coating to be considered “functionally transparent” because it withstands mechanical deformations required for the assembly, deployment, expansion, and placement of medical devices, without any adverse effect on the mechanical and biological functionality of the coated device. Further, its inertness, derived from the perfluorocarbon structure, contributes to its functionally transparent nature. The coating can be provided with various liquid or solid additives, can be loaded with large quantities of additives including a wide range of therapeutic agents, and has excellent drug elution characteristics when elutable additives are used. | 04-17-2014 |
20140128544 | Novel Heparin Entities and Methods of Use - The present invention relates to immobilized biologically active entities that retain a significant biological activity following manipulation. The invention also comprises a medical substrate comprising a heparin entity bound onto a substrate via at least one heparin molecule, wherein said bound heparin entity is heparinase-1 sensitive. | 05-08-2014 |
20140271775 | POROUS COMPOSITES WITH HIGH-ASPECT RATIO CRYSTALS - The present disclosure is directed toward composite materials comprising high aspect ratio habits of drug crystals which can be partially or fully extending into a substrate, and additionally, can be projecting from a substrate at an angle of about 20° to about 90°. The present disclosure is directed toward medical devices, such as medical balloons, comprising said composite and methods of using and making the same. The described composite can be used for the local treatment of vascular disease. The present disclosure is also directed toward paclitaxel crystals with a hollow acicular habit. | 09-18-2014 |
20140364404 | ARTICLES AND METHODS OF TREATING VASCULAR CONDITIONS - The present invention relates to articles and methods of treating vascular conditions with a thixotropic, turbid, bioactive agent-containing gel material capable of being essentially removed from an implantation site upon re-establishment of fluid flow at the implantation site. | 12-11-2014 |